Pioneer Group has partnered with global healthcare company Daiichi Sankyo to deliver a Golden Ticket designed to help accelerate innovations in novel therapeutic platform technologies, oncology, neuroscience and ophthalmology.

The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines, with robust research plans and potential for successful research development.

This event will announce the winner of this Golden Ticket alongside presentations from the semi-finalists, as well as keynote speakers from within Daiichi Sankyo. Following the presentations there will be opportunity for Q&A as well as a networking reception.